Colorectal cancer screening

Česká verzia

Authors: G. Vojtěchová ¹ ; Š. Suchánek ¹; T. Grega ¹; O. Májek ²; L. Dušek ²; M. Zavoral ¹
Authors place of work: Interní klinika 1. LF UK a ÚVN Praha ¹; Institut biostatistiky a analýz, LF a PřF MU, Brno ²
Published in the journal: Kardiol Rev Int Med 2014, 16(3): 235-239
Category: Internal Medicine

Summary

Colorectal cancer (CRC) is the second most common malignant disease in the Czech Republic. Most CRCs are sporadic and only 14– 19 % are associated with a genetic predisposition. Due to the relatively long carcinogenesis, premalignant lesions can be detected by screening and removed in time and CRC can thus be prevented. Colorectal cancer screening in the Czech Republic is undergoing continuous development. The basic tools currently used are either an immunochemical faecal occult blood test and a colonoscopy in the case of test positivity, or a primary screening colonoscopy. Since January 2014, citizens under the age of 70 have been actively invited to participate in the program. Patients with a higher risk of colorectal neoplasia are monitored within the dispensary programs.

Keywords:
colorectal cancer – screening – colonoscopy – Faecal Occult Blood Test – targeted invitation

Zdroje

1. Dušek L, Abrahámová J, Bortlíček Z et al. Epidemiologie, prevence a léčba kolorektálního karcinomu dle dostupných českých a mezinárodních dat. Praha: FN v Motole 2012.

2. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology 2010; 138: 2029– 2043. doi: 10.1053/ j.gastro.2010.01.057.

3. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169– 2180.

4. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta‑analysis. J Natl Cancer Inst 2005; 97: 1679– 1687.

5. Will JC, Galuska DA, Vinicor F et al. Colorectal cancer: Another complication of diabetes mellitus? Am J Epidemiol 1998; 147: 816– 825.

6. Heresbach D, Manfredi S, D'halluin PN et al. Review in depth and meta‑analysis of controlled trials on colorectal cancer screening by faecal occult blood test. Eur J Gastroenterol Hepatol 2006; 18: 427– 433.

7. Seeff LC, Nadel MR, Klabunde CN et al. Patterns and predictors of colorectal cancer test use in the adult U. S. population. Cancer 2004; 100: 2093– 2103.

8. Vepřeková G, Suchánek Š, Martínek J et al. Příprava střeva ke kolonoskopii. Gastroent Hepatol 2012; 66: 57– 62.

9. Wexner SD, Beck DE, Baron TH et al. A consensus document on bowel preparation before colonoscopy: prepared by a task force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). Surg Endosc 2006; 20: 1147– 1160.

10. Church JM. Effectiveness of polyethylene glycol antegrade gut lavage bowel preparation for colonoscopy‑ timing is the key! Dis Colon Rectum 1998; 41:1223– 1225.

11. Hendry PO, Jenkins JT, Diament RH. The impact of poor bowel preparation on colonoscopy: a prospective single centre study of 10 571 colonoscopies. Colorectal Dis 2007; 9: 745– 748.

12. Suchanek S, Majek O, Vojtechova G et al. Colorectal cancer prevention in the Czech Republic: time trends in performance indicators and current situation after 10 years of screening. Eur J Cancer Prev 2014; 23: 18–26. doi: 10.1097/CEJ.0b013e328364f203.

13. Zavoral M, Suchanek S, Majek O et al. Colorectal cancer screening: 20 years of development and recent progress. World J Gastroenterol 2014; 20: 3825–3834. doi: 10.3748/wjg.v20.i14.3825.

14. Kaminski MF, Regula J, Kraszewska E et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010; 362: 1795– 1803. doi: 10.1056/ NEJMoa0907667.

15. Atkin WS, Valori R, Kuipers EJ et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition‑ Colonoscopic surveillance following adenoma removal. In: Segnan N, Patnick J, von Karsa L. (EDS) European Union 2010: 274– 297. doi: 10.2772/ 1458.